News and Events

Nature Medicine

In patients with metastatic triple-negative #BreastCancer, atezolizumab + anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease.

@andreashr @GroupKyte @AmundJon @Oslounivsykehus @UniOslo_MED

https://www.nature.com

 

Oppløftende prøvemetode mot brystkreft : – Ville ikke stått her uten den

Guri de Lange and cancer researcher Jon Amund KyteGuri de Lange and cancer researcher Jon Amund Kyte

Guri de Lange er en av 68 deltakere i pasientstudien til kreftforsker Jon Amund Kyte.

FOTO: LASR HÅKON PEDERSEN / NRK

https://www.nrk.no

 

Stort framskritt i norsk brystkreftforskning

Generalsekretær i Kreftforeningen, Ingrid Stenstadvold Ross (t.v.), i samtale med Guri de Lange, Andreas Røsseland Hage og Jon Amund Kyte.

Foto: Hanne Marie Molde

https://kreftforeningen.no

 

Data from the ALICE trial published in Nature Medicine

The randomized, placebo-controlled ALICE trial investigated the effect of treating metastatic triple-negative breast cancer patients with a combination of the immune checkpoint inhibitor atezolizumab and chemotherapy. Conclusions from this trial, led by Jon Amund Kyte at Oslo University Hospital (OUH), have now been published in Nature Medicine in an article titled “Atezolizumab plus anthracyclin-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase IIb ALICE trial”.

Guri de Lange (tv) thanks the researchers Andreas Hagen Røssevold and Jon Amund Kyte for allowing her to take part in the ALICE study and is thus alive and well today - four years after she relapsed. Photo: Hanne Marie Molde

https://www.matrix-fkb.no/news

 

Public Defence: Cand.med Elin Aamdal

Image may contain: Nose, Cheek, Smile, Eyelash, Happy.

will be defending the thesis: Click here
“Treating metastatic melanoma with ipilimumab – Clinical activity, health-related quality of life and combination with a telomerase peptide vaccine

Trial Lecture
Prevention and early detection strategies for melanoma

Time and place: June 22, 2022 10:15 AM, Auditorium, Research building (K-building), The Norwegian Radium Hospital

Adjudication Committee
First opponent: Lecturer Lars Ny, Sahlgrenska University Hospital
Second opponent: Professor Ingvild Vistad, University of Bergen
Third member and chair of the evaluation committee: Adjunct Professor Knut Jørgen Labori, University of Oslo

Chair of defence
Professor Ludvig A. Munthe, Faculty of Medicine, University of Oslo

Principal supervisor
Jon Amund Kyte, overlege dr.med., Seksjonsleder, Seksjon for utprøvende kreftbehandling, Forskningsgruppeleder, Seksjon for kreftimmunologi

 

Interviews with Pharma Boardroom

Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team are conducting at Oslo University Hospital.

Click here

 

 

Webinar: Want to know more about breast cancer research?

Click here

 

 
Page visits: 970